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William B Isaacs27 and the International Consortium for Prostate Cancer GeneticsAbstract
Background: Genetic variants are likely to contribute to a portion of prostate cancer risk. Full elucidation of the
genetic etiology of prostate cancer is difficult because of incomplete penetrance and genetic and phenotypic
heterogeneity. Current evidence suggests that genetic linkage to prostate cancer has been found on several
chromosomes including the X; however, identification of causative genes has been elusive.
Methods: Parametric and non-parametric linkage analyses were performed using 26 microsatellite markers in each
of 11 groups of multiple-case prostate cancer families from the International Consortium for Prostate Cancer
Genetics (ICPCG). Meta-analyses of the resultant family-specific linkage statistics across the entire 1,323 families and
in several predefined subsets were then performed.
Results: Meta-analyses of linkage statistics resulted in a maximum parametric heterogeneity lod score (HLOD) of
1.28, and an allele-sharing lod score (LOD) of 2.0 in favor of linkage to Xq27-q28 at 138 cM. In subset analyses,
families with average age at onset less than 65 years exhibited a maximum HLOD of 1.8 (at 138 cM) versus a
maximum regional HLOD of only 0.32 in families with average age at onset of 65 years or older. Surprisingly, the
subset of families with only 2–3 affected men and some evidence of male-to-male transmission of prostate cancer
gave the strongest evidence of linkage to the region (HLOD= 3.24, 134 cM). For this subset, the HLOD was slightly
increased (HLOD= 3.47 at 134 cM) when families used in the original published report of linkage to Xq27-28
were excluded.
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Conclusions: Although there was not strong support for linkage to the Xq27-28 region in the complete set of
families, the subset of families with earlier age at onset exhibited more evidence of linkage than families with later
onset of disease. A subset of families with 2–3 affected individuals and with some evidence of male to male disease
transmission showed stronger linkage signals. Our results suggest that the genetic basis for prostate cancer in our
families is much more complex than a single susceptibility locus on the X chromosome, and that future
explorations of the Xq27-28 region should focus on the subset of families identified here with the strongest
evidence of linkage to this region.Background
Prostate cancer (PC) is the most common male cancer
in developed countries [1]. In the United States, each
year there are over 200,000 newly diagnosed cases and
over 30,000 deaths attributable to prostate cancer [2].
Family history, along with older age and African-
American ancestry, are the most important risk factors
established to date. Inherited genetic factors might ac-
count for a proportion of the familial risk, but it has
been very difficult to discover the actual genetic basis of
prostate cancer probably due to the large number of loci
involved, the incomplete and possibly low penetrance
associated with these loci, and the likely clinical and
genetic heterogeneity of this disease.
In 1996, the first prostate cancer linkage report impli-
cated chromosome 1q23-25 [3], but subsequent linkage
studies have found contradictory conclusions. In this
same year the International Consortium for Prostate
Cancer Genetics (ICPCG), consisting of researchers
from 11 groups around the world, was formed. With the
initial aim of examining linkage and trying to replicate
previous linkage findings the ICPCG pooled 1,323 pedi-
grees with clinically- (but not genetically-) defined “her-
editary prostate cancer” (HPC). Given the large number
of families in this dataset, it was hoped that this would
provide increased power to confirm or exclude linkage,
and to allow for informative linkage analyses of large
homogeneous subsets in an attempt to control for some
of the likely heterogeneity that would otherwise weaken
the ability to detect linkage. The ICPCG analysis of 775
families supported the finding of a prostate cancer–
susceptibility gene linked to 1q24-25 in a defined subset
of prostate cancer families with early age at onset, at
least 5 affected relatives and evidence of male-to-male
transmission [4]. The RNASEL gene was later implicated
as harboring rare variant alleles that increase risk of
prostate cancer and may account for this linkage signal
[5]. Evidence has been accumulating in support of
RNASEL as a prostate cancer risk locus, with several
recent large case–control and cohort studies and a
very large meta-analysis all showing significant associa-
tions of prostate cancer risk with polymorphisms in
this locus [6-10].Several other susceptibility loci presumed to contain
rare variants of large effect on individual risk of prostate
cancer have been suggested [3,4,11-42] and reviewed
elsewhere [30,41,42]. In addition, recent genome-wide
association studies (GWAS) have implicated multiple
loci at which there are common variants (single nucleo-
tide polymorphisms; SNPs) that are not necessarily func-
tional but are associated with small effects on individual
risk of prostate cancer [43-49]. For a review see Varghese
and Easton [50]. Work is proceeding to try to identify
more susceptibility loci, by GWAS using common SNP
risk alleles, by conventional linkage analyses aimed at
detecting genes with rare, high-penetrance risk alleles
and by whole exome and whole genome sequencing ana-
lyses that can be used in conjunction with linkage and
GWAS results.
In 1998, a study of 360 multiple-case families found
evidence for a prostate cancer susceptibility locus on
chromosome X in the region Xq27-q28 (HPCX) [38]. A
subset of 52 Finnish families from this study was used to
examine whether phenotypic subsets of families exhib-
ited different evidence for linkage to this region. This
study showed that families with no male-to-male
(NMM) transmission and late age of onset of prostate
cancer (> 65 years) exhibited stronger evidence of link-
age to the Xq27-28 region than did the complete set of
families [33]. There have been five replication studies,
four of which supported linkage of prostate cancer sus-
ceptibility to this region [6,21,51-53] with the study of
large Utah pedigrees yielding independent genome-wide
significant evidence of linkage [21], and one which did
not support linkage to this region [12]. A fine-mapping
study in the Finnish population examined association of
prostate cancer to microsatellite markers in the HPCX
Xq27-28 region using 108 independent prostate cancer
patients selected from families with multiple affected
men (55 were from the linkage study above) and 257
controls (anonymous, healthy male blood donors) from
the same Finnish population. Significant association was
observed for two markers in the region, DXS1205
(p = 0.0003) and bG82i1.1 (p = 0.0006), with stronger as-
sociation observed at DXS1205 in the subset of 60 cases
from families with no evidence of male-to-male
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markers with prostate cancer risk has been replicated in
an Ashkenazi Jewish founder population [6]. Positive
associations were observed for allele 135 of the bG82i1.1
marker (OR= 1.77, P = 0.01) and allele 188 of DXS1205
(OR= 1.65, P = 0.02) in 979 prostate cancer cases and
1,251 controls.
Under the Xq27-q28 linkage peak is a region of
~750 kb containing five SPANX genes (SPANX-A1, -A2,
-B, -C, and -D). The SPANX genes encode nucleus-
associated sperm proteins and their expression has been
detected in a variety of cancers. While they were origin-
ally suggested as candidate genes for the HPCX suscepti-
bility locus [54], more recent work has found no
association between prostate cancer and mutations in
any of these genes [55]. However, a more complex in-
volvement of these genes is possible. Putative candidate
genes for association with prostate cancer have been
found on other regions of the X chromosome.
Gudmundsson et al. conducted a genome-wide SNP
association study of prostate cancer in over 23,000 Ice-
landers followed by a separate replication study. Of the
two novel SNPs identified by this study, one, rs5945572,
was found on XP11.22 (odds ratio (OR) = 1.23) [56].
Eeles et al. also found association to this region in a
large GWAS [47]. However, the odds ratios for the risk
genotypes at this putative locus are quite small and not
likely to be responsible for the linkage signal observed
on Xq in highly aggregated pedigrees.
The aims of this study were to examine the evidence
for linkage of prostate cancer to chromosome X using
1,323 multiple-case prostate cancer families from the
ICPCG and genotyping a consensus map of 25 microsat-
ellite markers and using both parametric and non-
parametric allele-sharing linkage analyses. The pedigree
subsets evaluated were presence/absence of male-to-
male disease transmission (a surrogate for X-linked in-
heritance), Carter criteria of HPC [57,58], average age at
onset of affected men in the family (<65 years of age
or ≥ 65 years), and number of men in a family with con-
firmed PC. Determining whether any of these subsets
show stronger evidence of linkage to the region may
guide the selection of cases for future mutational ana-
lysis in this region.Methods
This analysis was performed on 1,323 families with her-
editary prostate cancer ascertained by 11 groups partici-
pating in the ICPCG. The process of ascertaining
families and confirming diagnosis of prostate cancer dif-
fered among the groups, but in all samples, men were
considered to be affected with prostate cancer only if
medical records or death certificates could confirm thediagnosis. The 11 groups that participated in this linkage
analysis are described elsewhere [59].
In the statistical analysis, all families were first ana-
lyzed together. In addition, several subsets of families
were created based on pedigree characteristics. A pedi-
gree was classified as satisfying the Carter criteria for
hereditary prostate cancer [57,58] if at least one of the
following conditions were met: 1) three consecutive gen-
erations of PC along a line of descent; 2) at least three
first-degree relatives with a diagnosis of PC; 3) two or
more relatives with a diagnosis of PC at age ≤ 55 years.
Pedigrees were also classified according to whether
transmission of PC in the family appeared consistent
with X-linked transmission (yes versus no versus un-
clear). A pedigree was considered to be consistent with
X-linked transmission if all affected males only had a
family history of prostate cancer on the maternal side of
the family so there was no evidence of male-to-male
transmission of a prostate cancer risk allele. A pedigree
was considered to be inconsistent with X-transmission if
the family contained at least one affected father-affected
son pair or if at least one affected son had an affected
paternal uncle or paternal grandfather (male-to-male
transmission). Pedigrees containing at least one male
who had a family history of prostate cancer on both
sides of his family (bilineal) were considered to be in-
consistent with X-transmission. Pedigrees containing
only a sibship of affected men with no information about
the prostate cancer history on the maternal or paternal
sides of the family were considered to be unclear for X-
transmission. Pedigrees were also classified as to
whether or not the average age at onset of affected men
in the family was less than 65 years of age.
Each group had genotyped a different set of markers
in the Xq27-q28 region. In order to use the available
genotype data without re-genotyping a common panel of
markers, a consensus map of the genetic markers from
the different groups was created as follows. A total of 26
different markers on chromosome Xq (see Additional
file 1: Table S1) were genotyped by ICPCG members.
For our analysis, the order of these markers was deter-
mined from UCSC Goldenpath (version hg13, released
Nov.14.2002). The marker distance was based on the de-
Code map [60]. All markers were successfully mapped
to Goldenpath or deCode maps and cM distances were
interpolated for some markers that were located on
Goldenpath but not on the deCode map (Table 1). Be-
cause some groups did not have either the first or last
markers from this consensus map, dummy non-
informative markers (i.e., homozygous for all subjects)
were used as anchors for these groups. This allowed us
to align all group’s linkage files to the consensus map,
allowing for different groups using different markers. All
groups computed parametric multipoint LOD scores
Table 1 Markers used in the analysis with map location information (base pair locations from the UCSC Goldenpath
version hg13, released Nov.14.2002 and cM locations from the deCode linkage map)
Marker bp Start bp End deCode cM Position interpolated cM position
DXS1216 66597577 66597945 82.98 82.98
DXS6800 76721582 76721893 86.84 86.84
DXS986 77422288 77422628 86.84 86.84
DXS990 91036325 91036548 94.92 94.92
DXS6789 93484970 93485285 96.95 96.95
DXS1106 100764898 100765284 101.56
DXS6797 105514006 105514365 104.57 104.57
GATA172D05 111199673 111199793 110.42 110.42
DXS8055 112690834 112691203 112.66
DXS1001 117811961 117812315 120.35 120.35
GATA165B12 118830243 118830577 122.11 122.11
DXS1047 127020308 127020598 131.44
DXS1192 136312813 136313015 142.03 142.03
DXS1232 137224883 137225141 144.25
DXS984 137576507 137576708 145.8 145.8
GATA31E08 138167161 138167460 147.38
DXS1205 138195175 138195518 147.46 147.46
DXS1227 138735290 138735546 150.37 150.37
DXS6751 138961389 138961667 151.02
DXS6798 139563750 139564153 152.76
DXS8106 140116944 140117293 154.35 154.35
DXS7127 140874035 140874578 156.62
DXS6806 141366644 141366944 158.09 158.09
DXS8043 141885707 141885926 159.62
MXMAFMA113ZF5 142386616 142387004 161.1
DXS1200 143602429 143602828 164.69 164.69
DXS297 143861118 143861312 165.05
DXS731 145029666 145029754 166.65
MXMAFM323YF1 145482291 145482634 167.28
DXS8091 145497860 145498194 167.3 167.3
AFM136yb10 (MXMAFM136YB10) 146107588 146107837 168.95
MXMAFMA107XF5 146244529 146244891 169.32
DXS1193 146275270 146275535 169.4 169.4
DXS1123 146381305 146381484 169.78
DXS8069 147408020 147408348 173.44 173.44
DXS8011 147637858 147638200 176
DXS8103 147886112 147886447 178.77 178.77
AFMa225xh9 (MXMAFMA225XH9) 148302283 148302628 179.88
MXMAFMA082XA5 148619715 148620129 180.74
DXS1073 151414197 151414518 188.22 188.22
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scores at 1 cM intervals along the consensus map, using
the GENEHUNTER-PLUS software [61-63] implemen-
ted in common PERL scripts. These analyses were
repeated using only the 964 families that were notincluded in the original publication of linkage to the
Xq27-28 region [38]. The output files containing
pedigree-specific parametric LOD scores and inter-
mediate files for computing nonparametric Kong and
Cox allele sharing LOD’s for each pedigree were sent
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the data for the linkage analyses. The planned analyses
were developed and approved by members of the
ICPCG.
The allele frequencies for each marker in each group
were estimated by counting alleles across all families, ig-
noring genetic relationships. All groups ran analyses
using the widely-spaced genome-wide screening (GWS)
markers (shown in bold text in Additional file 1: Table
S1 and Table 1). Since some groups had also genotyped
fine-mapping (FM) markers after finding suggestive evi-
dence for linkage, our primary analyses used the GWS
markers in order to attempt to eliminate any biases due
to different information content across datasets. We also
performed secondary analyses that included both GWS
and FM markers. Since individual groups had fine-
mapped at different densities and therefore obtained dif-
ferent levels of information content in their families, the
secondary analyses were quite variable across samples in
the amount of information available from the FM mar-
kers. This variability in marker density across studies
could result in bias and so the combined analyses using
the GWS markers are considered more reliable. We cre-
ated two marker maps, one for the GWS markers and
one for the FM markers (Table 1 shows the merged map
of the GWS and FM markers).
A parametric model for dominant X-linked inheritance
was used: the “Smith” model [3], with 2 liability classes,
adapted to affecteds-only, X-linkage and a sex-limited
trait. Multipoint parametric and non-parametric analyses
were performed using GENEHUNTER-PLUS. After
combining the results, multipoint heterogeneity LOD
scores (HLODs) [63] were computed using the LOD
scores from all sites. For the nonparametric allele-
sharing LODs, the Kong and Cox allele sharing statistics
were computed using output files from GENEHUNTER-
PLUS [62].
Results
In the nonparametric analyses, the analysis of all families
using the GWS marker set resulted in an allele-sharing
LOD of 2.0 in favor of linkage to Xq27-q28 at 138 cM,
which is well below the commonly accepted threshold
for claiming statistically significant evidence for linkage.
Non-parametric analyses using the fine mapping (FM)
marker set always resulted in the same or lower allele-Table 2 Nonparametric, maximum multipoint allele-sharing L
Number of affected males in family Family consistent with X-linka
2-3 0.26 (136 cM, 58)
4-5 0.12 (134 cM, 37)
6 or more 0.59 (176 cM, 9)sharing LODs (e.g. 1.22 at 125 cM in the complete data-
set). The subsets that resulted in higher allele-sharing
LODs for the GWS markers were the 732 families with
2–3 affecteds (allele-sharing LOD=2.56 at 134 cM), the
627 families where mean age at onset was <65 years
(allele-sharing LOD=2.34 at 138 cM), and the subset of
288 families with 2–3 affecteds that appeared to exhibit
male-to-male transmission (allele-sharing LOD=3.49 at
134 cM). The subsets of families that appeared to exhibit
patterns of prostate cancer consistent with X-linked in-
heritance did not have high positive allele-sharing LODs
(Table 2).
In the parametric, multipoint HLOD analyses, when
all families were analyzed using the GWS marker set,
the maximum HLOD was 1.28 at 138 cM (Figure 1a).
When the FM marker set was used, the maximum
HLOD was 0.45 at 125 cM in the complete set of
families.
Subset analyses yielded larger HLOD scores in some
subsets under this 2-liability class dominant parametric
model. When using the GWS marker set, the subset
of 104 families consistent with X-linked transmission,
the 484 unclear families and the 735 non-X-linked
(male-to-male transmission) families all gave positive
HLODs, with a stronger signal observed in the latter
group of families. When the FM marker set was used,
the same pattern was observed: the subset of X-linkage
transmission families gave a maximum HLOD=0.246
at 132 cM, the unclear families gave a maximum
HLOD=0.142 at 143 cM, and the non-X-linkage fam-
ilies (male-to-male transmission families) yielded a
maximum HLOD=0.62 at 153 cM. The subset of 627
families with mean age at onset 65 years or younger
gave HLOD=1.8 at 138 cM using the GWS markers.
The 696 families with mean age greater than 65 had
maximum HLOD=0.32 at 120 cM. Subdivisions based
on the Carter criteria alone were not highly correlated
with linkage evidence. Number of affected males in the
family had a larger effect on linkage evidence, particu-
larly when combined with pattern of transmission. The
732 families with 2–3 affecteds per family had max-
imum HLOD=2.01 at 134 cM, whereas the 438 fam-
ilies with 4–5 affected males had HLOD=0.1 at
168 cM and the 153 families with 6 or more affected
males had HLOD=1.4 at 153 cM. Consistent with the
non-parametric analyses, the strongest evidence forODs (location, number of families) for subsets of families
ge Family unclear Family not consistent with X-linkage
0.17 (127 cM, 386) 3.49 (134 cM, 288)
0.71 (83 cM, 93) 0.19 (109 cM, 308)
0.74 (109 cM, 5) 1.70 (153 cM, 139)
Figure 1 Multipoint HLODs using the GWS marker set and the two-liability class parametric model: a) using all families, b) in the subset
of families with 2–3 affected males and possible male-to-male transmission of prostate cancer, c) in the subset of families that were not included
in the original HPCX linkage paper [3,38] with 2–3 affected males and possible male-to-male transmission of prostate cancer, d) in the subset of
families with 2–3 affected males that also meet the Carter criteria, e) in the subset of families with 2–3 affected males that also meet the Carter
criteria and were not included in the original HPCX linkage paper [38]. Panel f is from the UCSC Genome Browser (http://genome.ucsc.edu) on
the Human February 2009 (GRCh37/hg19) Assembly of the human genome and shows the 2-LOD drop linkage interval from the HLOD graph in
panel c. This region extends from approximately 122 cM to 144 cM, bounded by markers GATA165B12 and DXS1232, spanning base pair
positions 120877968 to 139280361.
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3 affected males and at least some evidence of male-
to-male transmission: maximum multipoint HLOD=
3.24 at 134 cM (Figure 1b). Interestingly, when the
analysis of this subset was restricted to the 248 fam-
ilies that were not included in the originally published
linkage study [38], the maximum multipoint HLOD
increased slightly to 3.47 at 134 cM, which exceeds
the 3.3 value suggested by Lander and Kruglyak [64]
for genome-wide significance (Figure 1c). The subset
of 330 families with 2–3 affected males who also met
the Carter criteria gave similarly strong linkage results
with a maximum multipoint HLOD=2.38 at 137 cM
in all such families (Figure 1d) and 2.74 at 138 cM in
the 284 families in this subset that were not included
in the original X-linkage publication [38] (Figure 1e).Discussion
In the analyses presented here, there appeared to be lit-
tle distinction between families with phenotypic segrega-
tion patterns consistent with X-linked inheritance (no
male-to-male transmission) or those with evidence of
male-to-male transmission when considering linkage
evidence provided by those subsets of families for a PC
susceptibility locus at Xq27-q28. Families with smaller
numbers of affected men appeared to contribute the
most evidence to linkage in this region. While classifica-
tion of each family based on proportion of affected men
out of total men old enough to be affected might provide
more homogeneous subsets, this was not feasible for this
study given the many sources of families with quite dif-
ferent ascertainment schemes and different degrees of
completeness of pedigree data collection. In addition,
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and is quite common, we are only able to assign “un-
affected” status to men who are over the age of 75 years
and who have a normal digital-rectal exam and normal
PSA at that advanced age. There are small numbers of
such well-characterized, elderly unaffected men in this
set of families and most of the families do not have any
of them, which would make a proportion misleading.
Families with 2–3 affecteds per family had maximum
HLOD=2.01 at 134 cM. However, the strongest sugges-
tion of linkage was observed in both the parametric and
non-parametric analyses in families with 2–3 affecteds
and possible male-to-male transmission. This pattern
was observed whether we included the families from the
initial linkage publication in the analysis or not. This
subset of families, when excluding the families from the
original linkage publication, had a multipoint HLOD of
3.47 at 134 cM. The HLOD in these new families was
slightly over the Lander and Kruglyak threshold of 3.3
for genome-wide “significant” linkage but this threshold
does not account for our multiple testing of different
subsets, which likely requires a larger threshold to claim
robust statistical evidence of linkage. However, this level
of significance would meet the Lander and Kruglyak
threshold for replication of a previously significant link-
age (p = 0.01 or a LOD of approximately 1.0) even after
correction for the multiple analyses. One candidate
locus, SPANXB1, lies under this linkage peak. Since
prostate cancer is fairly common, our analysis models
allowed for the presence of sporadic cases in the families
and the families with possible male-to-male transmission
included some bilineal families. Thus, it is possible that
in the male-to-male transmission family subsets, some
families show sharing of X-chromosome markers among
the maternally-related affected relative pairs in these
pedigrees and no sharing among the paternally related
affected pairs, thus giving evidence for X-linkage in these
families. It appears that the evidence for linkage to
Xq27-q28 is being driven mainly by families not
included in the original linkage study [38] and these new
families have had very few FM markers genotyped in this
region (Additional file 1: Table S1). Interestingly, when
the FM markers were added to the analyses of these
same subsets, the HLODs no longer reached the Lander
and Kruglyak genome-wide significance threshold. The
information content when using only the GWS markers
was fairly consistent across all families. However, when
the FM markers were added, the information content
differed greatly across groups of families and between
the original and new families. An additional difference
between the original and new families is that the families
from the original linkage study had no markers geno-
typed more centromeric than 144 cM. Thus, it is pos-
sible that the differing position of linkage peaks betweenthe analyses of the original and new families coupled
with differential linkage information across these data-
sets is contributing to the inconsistent results.
Our complete prostate cancer pedigree resource, with
additional fine-mapping in the Xq27-28 region, pro-
vided, at best, modest suggestive evidence for linkage to
this region. However, subsets of families with fewer
affected individuals and paradoxically, families with
some possible evidence of male-to-male disease trans-
mission showed stronger linkage signals. This same re-
sult was observed in the analysis of very large Utah
pedigrees [21], in which the best evidence for linkage
was observed in the set of pedigrees with a maximum of
5 generations and an average of 2.5 genotyped prostate
cancer cases. Although our finding of somewhat stron-
ger linkage evidence in families with male-to-male dis-
ease transmission might not be sensible when
considering a single locus on the X chromosome causing
disease, this might indicate a more complex interaction
between other susceptibility loci situated on the auto-
somes and a locus at Xq27-28. However, this finding
might simply be due to high locus heterogeneity and/or
important environmental risk factors in causation of
prostate cancer, such that families segregating an X-
linked risk allele may have at least one affected family
member who is not a carrier of this risk allele and who
is paternally related to another affected family member.
Figure 2 shows one such pedigree that exhibits both po-
tential male-to-male transmission and potential maternal
inheritance of PC. In this family, with a maximum LOD
of 1.7 in the HPCX region, all maternally related affected
males share a linked haplotype in this region and the
one paternally-related affected male does not share this
haplotype. Finally, it is possible that the true causal allele
in this region lies within the pseudoautosomal regions
PAR2, which is near this linkage peak. Since female car-
riers cannot become affected with prostate cancer and
since no marker loci have been genotyped in the PAR2
region in our families, our current data are inadequate
for resolving this.
Conclusions
Although our results do not provide strong evidence for
a major prostate cancer susceptibility gene located in
this region of Xq27-28, there is some evidence for a
locus that may contribute to risk in families with 2–3
affecteds and in some larger families such as the one in
Figure 2. This locus does not appear linked to prostate
cancer risk in a high proportion of larger HPC families
with many affected males. Given these observations,
gene identification efforts in highly penetrant families
would be better targeted to other chromosomal regions,
perhaps using whole-exome or whole genome DNA se-
quencing techniques. Gene identification at Xq27-28
Figure 2 Pedigree that exhibits both potential male-to-male transmission and potential maternal inheritance of prostate cancer. In this
family, with a maximum LOD of 1.7 in the HPCX region, all five maternally related affected males share a linked haplotype (shaded black) in this
region and the one paternally-related affected male does not share this haplotype. The numbers in the shapes are liability classes based on
affection status and age.
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http://www.biomedcentral.com/1471-2350/13/46should be aimed at the families with smaller numbers of
affected men identified here as belonging to the most
strongly linked subset and to specific large families with
strongly positive LOD scores.
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